RxDoctor Payments DataLook up a doctor →

Christopher Green, MD

General Practice · Lebanon, INNPI 1902284342

Payments from drug & device makers

$11,850in general payments, 2019–2025

Across 734 payments — averaging $16.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Lilly USA, LLC$1K
  • Amgen$979
  • AstraZeneca$841
  • Novo Nordisk$746
  • GSK$590
  • plus $5K from 54 others

What the payments were for

  • Food & beverage$11,850100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)172$2,380
Lilly USA, LLC79$1,153
Amgen64$979
AstraZeneca40$841
Novo Nordisk56$746
GSK35$590
Johnson & Johnson26$468
Boehringer Ingelheim17$289
Takeda Pharmaceuticals U.S.A., Inc.16$285
Sanofi-aventis U.S. LLC15$271
Dexcom, Inc.13$241
Exact Sciences13$233
Bayer12$230
Pfizer15$230
Merck14$194
Otsuka America Pharmaceutical, Inc.10$164
Abbott8$159
Teva Pharmaceuticals USA, Inc.5$152
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)8$146
Biohaven Pharmaceuticals, Inc.11$137
Nestle Healthcare Nutrition Inc.5$127
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC7$104
Eisai Inc.5$92
Mylan Specialty L.p.5$89
Aimmune Therapeutics, Inc.4$88
Novartis6$88
Phathom Pharmaceuticals, Inc.4$85
Lundbeck LLC4$81
Sumitomo Pharma America, Inc.4$69
Medtronic4$69
Shield Therapeutics Inc1$65
Vertex2$55
Xeris Pharmaceuticals, Inc.3$53
Supernus Pharmaceuticals, Inc.4$52
Biohaven Pharmaceutical Holding Company Ltd.3$51
Radius Health, Inc.3$50
Axsome Therapeutics, Inc.2$46
Astellas Pharma US Inc2$44
Jazz Pharmaceuticals Inc.2$37
Idorsia Pharmaceuticals US Inc2$37
Noven Therapeutics, LLC2$36
Ironshore Pharmaceuticals Inc.2$33
Antares Pharma, Inc.2$32
Si-bone, Inc.1$31
Daiichi Sankyo Inc.2$30
Edwards Lifesciences1$30
Almatica Pharma LLC1$26
Currax Pharmaceuticals LLC2$24
Bioventus LLC1$24
Argenx US, Inc.1$22
Kyowa Kirin, Inc.1$22
Gilead1$21
Verona Pharma, Inc.1$20
Boston Scientific1$20
Sanofi Pasteur Inc.1$19
Corium, LLC2$19
Ironwood Pharmaceuticals, Inc1$19
Ardelyx, Inc.1$19
Azurity Pharmaceuticals, Inc.1$17
Paratek Pharmaceuticals, Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,850 in reported general payments places this provider in the 95th percentile of 1,558 general practice providers in Indiana.

See all general practice providers in Indiana

Medicare billing

Part B allowed, 2024
$91,939
Medicare patients
160
Services billed
1,505

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide132$172,598
OzempicSemaglutide116$138,430
JardianceEmpagliflozin90$97,542
EliquisApixaban80$70,804
FarxigaDapagliflozin Propanediol38$43,570
XareltoRivaroxaban34$31,977
Breztri AerosphereBudesonide/Glycopyr/Formoterol41$29,116
JanuviaSitagliptin Phosphate27$25,672
RybelsusSemaglutide13$24,265
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog34$21,547
Soliqua 100-33Insulin Glargine/Lixisenatide16$20,096
TrulicityDulaglutide17$19,216
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$17,890
EntrestoSacubitril/Valsartan19$16,979
Tresiba Flextouch U-100Insulin Degludec17$16,511

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,153$191,813149 claims
Novo NordiskOzempic, Rybelsus$746$162,695129 claims
Boehringer IngelheimJardiance$289$97,54290 claims
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta$841$82,98994 claims
PfizerEliquis, Paxlovid$230$73,51491 claims
Johnson & JohnsonXarelto$468$31,97734 claims
MerckJanuvia$194$25,67227 claims
AbbVieCreon, Linzess$2,380$21,94224 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$271$20,09616 claims
GSKTrelegy Ellipta$590$17,89029 claims
NovartisEntresto$88$16,97919 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$285$5,46114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,558 general practice providers in Indiana.

Other general practice in Lebanon

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →